US Market Report for Cellular Allografts 2017; New Report Launched

DrugPipeline.net has announced the addition of “US Market Report for Cellular Allografts 2017 - MedCore” research report to their website DrugPipeline.net


Bangalore, Karnataka -- (SBWIRE) -- 03/15/2017 -- General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions

The cellular allograft market is segmented into usage for the cervical and lumbar regions of the spine. The cellular allograft market is the fastest growing within the overall bone graft market. By far, the largest market segment was for lumbar usage, with the remainder going to cervical. Both segments are growing rapidly, which will continue over the forecast period. Contributing to the larger market share of the lumbar segment is that much more graft material is required for lumbar usage. Use of stem cell grafts outside of the spine will also see growth; this should bring an even greater market potential for stem cell grafts.

The high average selling price (ASP) of cellular allografts has provided incentives for new players to enter the market. The synergies between the bone graft substitute materials such as allografts and DBMs provide a platform for companies that operate within those markets to pursue growth by expanding into cellular allograft market.

Cellular allografts consist of allograft bone combined with adipose derived mesenchymal stem cells; or may refer to HCT/P (Human Cells, Tissues, and Cellular and Tissue-based Product) comprised of viable cells within a cortical cancellous bone matrix. The viable cell bone matrix (VCBM) is a cryopreserved cancellous bone combined with demineralized cortical bone matrix. Their key characteristic in regards to bone repair is that they provide osteogenic properties.

Spanning over 462 pages "US Market Report for Cellular Allografts 2017 - MedCore" report covers Executive Summary, U.S. Orthopedic Biomaterials Market Overview, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Cellular Allograft Market, Appendix. The Report Covered Companies Are - Medtronic, Genzyme, DePuy Synthes, Anika Therapeutics, Ferring Pharmaceuticals, Stryker, NuVasive, Bioventus, Zimmer Biomet, Integra LifeSciences, RTI Surgical, Fidia Pharmaceuticals, MTF, Orthofix, Arthrex, AlloSource, Aastrom, Baxter, Harvest Technologies, Wright Medical, Bacterin International, Arteriocyte, Exactech, LifeNet Health, Biocomposites, Alphatec Spine, Celling Biosciences, Globus Medical, Nuo Therapeutics, K2M

For more information Visit at: http://www.drugpipeline.net/idata-research/us-market-report-cellular-allografts-2017-medcore

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.